The road to virtual control groups and the importance of proper body weight selection

Alexander Gurjanov; Lea A. I. Vaas; Thomas Steger-Hartmann

doi:10.14573/altex.2403141

pdf sup

Published: Oct 22, 2024

DOI: https://doi.org/10.14573/altex.2403141

Keywords:

historical control data, virtual control groups, systemic toxicity study, body weight, statistical modeling

Alexander Gurjanov , Lea A. I. Vaas, Thomas Steger-Hartmann
[show affiliations]

Abstract

Virtual control groups (VCGs) created from historical control data (HCD) can reduce the number of concurrent control group animals needed in regulatory toxicity studies by up to 25%. This study investigates the performance of VCGs on statistical outcomes of body weight development between treatment and control groups in legacy studies. The objective is to reproduce the statistical outcomes of 28-day sub-chronic studies (legacy studies) after replacing the concurrent control group with virtual ones. In rodent toxicity studies initial body weight is used as surrogate for the age of animals. For the assessment of VCG-sampling methods, three different approaches were explored: (i) sampling VCGs from the entire HCD, ignoring initial body weight information of the legacy study, (ii) sampling from HCD by matching the legacy study’s initial body weights, and (iii) sampling from HCD with assigned statistical weights derived from legacy study initial body weight information. The ability to reproduce statistical outcomes using virtual controls was determined by the congruence between the legacy study and the HCD weight distribution: regardless of the chosen approach, the ability to reproduce statistical outcomes was high for VCGs when the legacy study’s initial body weight distribution was similar to the HCD’s. When the initial body weight range of the legacy study was at the extreme ends of the HCD’s distribution, the weighted sampling approach was superior. This article demonstrates the importance of proper HCD matching by the legacy study’s initial body weight and discusses conditions to accurately reproduce body weight development.

Plain language summary
Animal control data from past studies performed in a standardized manner can be used to create virtual control groups (VCGs) to use in new studies instead of control animals. This approach can reduce the number of study animals needed by up to 25%. This study assessed the performance of VCGs selected by body weight in rat studies. The objective was to reproduce the original study results as closely as possible after replacing the original control group values with VCGs from a pool of historical control values. Several methods for selecting control animal data to create VCGs were compared. Among these, assigning statistical weights to the sampling pool yielded the best performance. Ideally, the body weight distributions on day 1 of the study should be similar between the VCG and the original study animals. This article shows that proper selection of VCGs can yield reliable study data with fewer animals.

How to Cite

Gurjanov, A., Vaas, L. A. I. and Steger-Hartmann, T. (2024) “The road to virtual control groups and the importance of proper body weight selection”, ALTEX - Alternatives to animal experimentation, 41(4), pp. 660–665. doi: 10.14573/altex.2403141.

Issue

Vol. 41 No. 4 (2024)

Section

Short Communications

This work is licensed under a Creative Commons Attribution 4.0 International License.

Articles are distributed under the terms of the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is appropriately cited (CC-BY). Copyright on any article in ALTEX is retained by the author(s).

References

Dunnett, C. W. (1955). A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 50, 1096-1121. doi:10.1080/01621459.1955.10501294

Du Sert, N. P., Ahluwalia, A., Alam, S. et al. (2020). Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol 18, e3000411. doi:10.1371/journal.pbio.3000411

Golden, E., Allen, D., Amberg, A. et al. (2024). Toward implementing virtual control groups in nonclinical safety studies: Workshop report and roadmap to implementation. ALTEX 41, 282-301. doi:10.14573/altex.2310041

Gurjanov, A., Kreuchwig, A., Steger-Hartmann, T. et al. (2023). Hurdles and signposts on the road to virtual control groups – A case study illustrating the influence of anesthesia protocols on electrolyte levels in rats. Front Pharmacol 14, 1142534. doi:10.3389/fphar.2023.1142534

Gurjanov, A. (2024) VCG Initial Body Weight [Software]. GitHub. https://github.com/bayer-group/vcg-initbw

Gurjanov, A., Vieira-Vieira, C., Vienenkoetter, J. et al. (2024). Replacing concurrent controls with virtual control groups in rat toxicity studies. Regul Toxicol Pharmacol 148, 105592. doi:10.1016/j.yrtph.2024.105592

Hamada, C. (2018). Statistical analysis for toxicity studies. J Toxicol Pathol 31, 15-22. doi:10.1293/tox.2017-0050

Hoffman, W. P., Ness, D. K., van Lier, R. B. L. (2002). Analysis of rodent growth data in toxicology studies. Toxicol Sci 66, 313-319. doi:10.1093/toxsci/66.2.313

Hothorn, L. A. (2016). The two-step approach – a significant ANOVA F-test before Dunnett’s comparisons against a control – is not recommended. Commun Stat Theory Methods 45, 3332-3343. doi:10.1080/03610926.2014.902225

Howard, B. R. (2002). Control of variability. ILAR J 43, 194-201. doi:10.1093/ilar.43.4.194

ICH (2009). Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3 (R2). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. https://bit.ly/4dmQujM

Jacob Filho, W., Lima, C. C., Paunksnis, M. R. R. et al. (2018). Reference database of hematological parameters for growing and aging rats. Aging Male 21, 145-148. doi:10.1080/13685538.2017.1350156

Kluxen, F. M., Weber, K., Strupp, C. et al. (2021). Using historical control data in bioassays for regulatory toxicology. Regul Toxicol Pharmacol 125, 105024. doi:10.1016/j.yrtph.2021.105024

McCutcheon, J. E. and Marinelli, M. (2009). Age matters. Eur J Neurosci 29, 997-1014. doi:10.1111/j.1460-9568.2009.06648.x

Namdari, R., Jones, K., Chuang, S. S. et al. (2021). Species selection for nonclinical safety assessment of drug candidates: Examples of current industry practice. Regul Toxicol Pharmacol 126, 105029. doi:10.1016/j.yrtph.2021.105029

OECD (2008). Test No. 407: Repeated Dose 28-Day Oral Toxicity Study in Rodents. OECD Guidelines for the Testing of Chemicals, Section 4. OECD Publishing, Paris. doi:10.1787/9789264070684-en

OECD (2018). Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents. OECD Guidelines for the Testing of Chemicals, Section 4. OECD Publishing, Paris. doi:10.1787/9789264070707-en

Russell, W. M. S. and Burch, R. L. (1959). The Principles of Humane Experimental Technique. Methuen. https://caat.jhsph.edu/the-principles-of-humane-experimental-technique-2/

Steger-Hartmann, T., Kreuchwig, A., Vaas, L. et al. (2020). Introducing the concept of virtual control groups into preclinical toxicology testing. ALTEX 37, 343-349. doi:10.14573/altex.2001311

Steger-Hartmann, T. and Clark, M. (2023). Can historical control group data be used to replace concurrent controls in animal studies? Toxicol Pathol 01926233231208987. doi:10.1177/01926233231208987

Talbot, S. R., Biernot, S., Bleich, A. et al. (2020). Defining body-weight reduction as a humane endpoint: A critical appraisal. Lab Anim 54, 99-110. doi:10.1177/0023677219883319

Wolford, S., Schroer, R., Gallo, P. et al. (1987). Age-related changes in serum chemistry and hematology values in normal Sprague-Dawley rats. Fundam Appl Toxicol 8, 80-88. doi:10.1016/0272-0590(87)90102-3

Wright, P. S., Smith, G. F., Briggs, K. A. et al. (2023). Retrospective analysis of the potential use of virtual control groups in preclinical toxicity assessment using the eTOX database. Regul Toxicol Pharmacol 138, 105309. doi:10.1016/j.yrtph.2022.105309

Most read articles by the same author(s)

Uwe Marx, Tommy B. Andersson, Anthony Bahinski, Mario Beilmann, Sonja Beken, Flemming R. Cassee, Murat Cirit, Mardas Daneshian, Susan Fitzpatrick, Olivier Frey, Claudia Gaertner, Christoph Giese, Linda Griffith, Thomas Hartung, Minne B. Heringa, Julia Hoeng, Wim H. de Jong, Hajime Kojima, Jochen Kuehnl, Marcel Leist, Andreas Luch, Ilka Maschmeyer, Dmitry Sakharov, Adrienne J. A. M. Sips, Thomas Steger-Hartmann, Danilo A. Tagle, Alexander Tonevitsky, Tewes Tralau, Sergej Tsyb, Anja van de Stolpe, Rob Vandebriel, Paul Vulto, Jufeng Wang, Joachim Wiest, Marleen Rodenburg, Adrian Roth, Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing , ALTEX - Alternatives to animal experimentation: Vol. 33 No. 3 (2016)
Mario Beilmann, Harrie Boonen, Andreas Czich, Gordon Dear, Philip Hewitt, Tomas Mow, Peter Newham, Teija Oinonen, Francois Pognan, Adrian Roth, Jean-Pierre Valentin, Freddy Van Goethem, Richard Weaver, Barbara Birk, Scott Boyer, Francesca Caloni, Alice Chen, Raffaella Corvi, Mark Cronin, Mardas Daneshian, Lorna Ewart, Rex Fitzgerald, Geraldine Hamilton, Thomas Hartung, Joshua Kangas, Nynke Kramer, Marcel Leist, Uwe Marx, Sebastian Polak, Costanza Rovida, Emanuela Testai, Bob van der Water, Paul Vulto, Thomas Steger-Hartmann, Optimizing drug discovery by investigative toxicology: Current and future trends , ALTEX - Alternatives to animal experimentation: Vol. 36 No. 2 (2019)
Alice Krebs, Tanja Waldmann, Martin F. Wilks, Barbara M. A. van Vugt-Lussenburg, Bart van der Burg, Andrea Terron, Thomas Steger-Hartmann, Joelle Ruegg, Costanza Rovida, Emma Pedersen, Giorgia Pallocca, Mirjam Luijten, Sofia B. Leite, Stefan Kustermann, Hennicke Kamp, Julia Hoeng, Philip Hewitt, Matthias Herzler, Jan G. Hengstler, Tuula Heinonen, Thomas Hartung, Barry Hardy, Florian Gantner, Ellen Fritsche, Kristina Fant, Janine Ezendam, Thomas Exner, Torsten Dunkern, Daniel R. Dietrich, Sandra Coecke, Francois Busquet, Albert Braeuning, Olesja Bondarenko, Susanne H. Bennekou, Mario Beilmann, Marcel Leist, Template for the description of cell-based toxicological test methods to allow evaluation and regulatory use of the data , ALTEX - Alternatives to animal experimentation: Vol. 36 No. 4 (2019)
Alice Krebs, Tanja Waldmann, Martin F. Wilks, Barbara M. A. van Vugt-Lussenburg, Bart van der Burg, Andrea Terron, Thomas Steger-Hartmann, Joelle Ruegg, Costanza Rovida, Emma Pedersen, Giorgia Pallocca, Mirjam Luijten, Sofia B. Leite, Stefan Kustermann, Hennicke Kamp, Julia Hoeng, Philip Hewitt, Matthias Herzler, Jan G. Hengstler, Tuula Heinonen, Thomas Hartung, Barry Hardy, Florian Gantner, Ellen Fritsche, Kristina Fant, Janine Ezendam, Thomas Exner, Torsten Dunkern, Daniel R. Dietrich, Sandra Coecke, Francois Busquet, Albert Braeuning, Olesja Bondarenko, Susanne H. Bennekou, Mario Beilmann, Marcel Leist, Erratum to Template for the Description of Cell-Based Toxicological Test Methods to Allow Evaluation and Regulatory Use of the Data , ALTEX - Alternatives to animal experimentation: Vol. 37 No. 1 (2020)
Uwe Marx, Takafumi Akabane, Tommy B. Andersson, Elizabeth Baker, Mario Beilmann, Sonja Beken, Susanne Brendler-Schwaab, Murat Cirit, Rhiannon David, Eva-Maria Dehne, Isabell Durieux, Lorna Ewart, Suzanne C. Fitzpatrick, Olivier Frey, Florian Fuchs, Linda G. Griffith, Geraldine A. Hamilton, Thomas Hartung, Julia Hoeng, Helena Hogberg, David J. Hughes, Donald E. Ingber, Anita Iskandar, Toshiyuki Kanamori, Hajime Kojima, Jochen Kuehnl, Marcel Leist, Bo Li, Peter Loskill, Donna L. Mendrick, Thomas Neumann, Giorgia Pallocca, Ivan Rusyn, Lena Smirnova, Thomas Steger-Hartmann, Danilo A. Tagle, Alexander Tonevitsky, Sergej Tsyb, Martin Trapecar, Bob van de Water, Janny van den Eijnden-van Raaij, Paul Vulto, Kengo Watanabe, Armin Wolf, Xiaobing Zhou, Adrian Roth, Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development , ALTEX - Alternatives to animal experimentation: Vol. 37 No. 3 (2020)
Thomas Steger-Hartmann, Annika Kreuchwig, Lea Vaas, Jörg Wichard, Frank Bringezu, Alexander Amberg, Wolfgang Muster, Francois Pognan, Chris Barber, Introducing the concept of virtual control groups into preclinical toxicology testing , ALTEX - Alternatives to animal experimentation: Vol. 37 No. 3 (2020)
Katharine Briggs, Nicolas Bosc, Tima Camara, Carlos Diaz, Phil Drew, William C. Drewe, Jan Kors, Erik van Mulligen, Manuel Pastor, Francois Pognan, Jordi Ramon Quintana, Sirarat Sarntivijai, Thomas Steger-Hartmann, Guidelines for FAIR sharing of preclinical safety and off-target pharmacology data , ALTEX - Alternatives to animal experimentation: Vol. 38 No. 2 (2021)
Diana Karwelat, Julia Kühnlenz, Thomas Steger-Hartmann, Remi Bars, Helen Tinwell, Uwe Marx, Sophie Bauer, Oliver Born, Marian Raschke, A rodent thyroid-liver chip to capture thyroid toxicity on organ function level , ALTEX - Alternatives to animal experimentation: Vol. 40 No. 1 (2023)
Julia Kühnlenz, Diana Karwelat, Thomas Steger-Hartmann, Marian Raschke, Sophie Bauer, Özlem Vural, Uwe Marx, Helen Tinwell, Remi Bars, A microfluidic thyroid-liver platform to assess chemical safety in humans , ALTEX - Alternatives to animal experimentation: Vol. 40 No. 1 (2023)
Emily Golden, David Allen, Alexander Amberg, Lennart T. Anger, Elizabeth Baker, Szczepan W. Baran, Frank Bringezu, Matthew Clark, Guillemette Duchateau-Nguyen, Sylvia E. Escher, Varun Giri, Armelle Grevot, Thomas Hartung, Dingzhou Li, Laura Lotfi, Wolfgang Muster, Kevin Snyder, Ronald Wange, Thomas Steger-Hartmann, Toward implementing virtual control groups in nonclinical safety studies , ALTEX - Alternatives to animal experimentation: Vol. 41 No. 2 (2024)

Article Sidebar

Main Article Content

Abstract

Article Details

Most read articles by the same author(s)